Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree!!!
Lol. Not going to happen my friend. Just bought me a ticket. I'm buying 450 mil amfe shares all day tomorrow lol.
Yep I was able to grab me 52000 more at .19
Magic on July 31 we hit a 52wk high of .226 the next two days were red pulling back down to .1455. Aug 9 we hit another 52 wk high .235 we are now in our second day of it pulling back. We will be heading north soon. Gl to you. AMFE strong
I noticed that only otcmarkets has the PR and the news really hasn't hit anywheres else. This can make for a good run come Monday. Might still be able to get some cheapies when funds or available
Money don't clear till Monday. Prices so cheap right.
Thanks. I've been in since .013 been averaging up since, now sit at .06. I just don't post much. Steady doing DD, reading post, and studying the company. As of yesterday I just convinced 4 friends of mine to each invest 10k in AMFE.
Go for it I'm throwing 10k Monday when funds clear
I'm adding more Monday when my 10k clears. Price doesn't really matter with as much potential AMFE has. I would just pull the trigger now if I could. The longer you wait the higher the pps will be
Agreed!
The number of authorized shares of capital stock of the Company will be increased to one billion five hundred ten million (1,510,000,000), one billion five hundred million (1,500,000,000) of which will be authorized as shares of Common Stock and ten million (10,000,000) shall be authorized as shares of preferred stock of the Company. The Board of Directors believes the Authorized Increase is necessary and advisable in order to maintain our financing and capital raising ability.
THORNTON, CO -- (Marketwired) -- 02/01/16 -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the Company's EnerPlex™ series of consumer products, announced today the Company's preliminary fourth quarter and full year revenue results for the period ended December 31, 2015.
The Company posted its highest recorded quarterly net revenue of $2.4M in the fourth quarter of 2015, an approximately 90% increase over third quarter of $1.25M. On a full year basis, the Company reported net revenue of $6.5M, a growth of approximately 23% over 2014. Specifically, the EnerPlex™ brand consumer product line continued to realize growing consumer acceptance, contributing nearly the entirety of the fourth quarter revenue and approximately 90% of the full year 2015 revenue.
BOOM!!! NEWS!!!
Ascent Solar Announces Strongest Quarterly Product Revenue in Corporate History; Preliminary Q4-2015 Net Revenue of $2.4M Represents Approximately 90% Growth Over the Third Quarter of 2015
Ascent Solar Fully Retires Senior Secured Convertible Notes
1/28/16, 5:00 AM
THORNTON, CO -- (Marketwired) -- 01/28/16 -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the Company's EnerPlex™ series of consumer products, announced today that the Company has fully retired it's senior secured convertible notes ("Notes"). The Company had previously announced on December 22, 2015 that the remaining principal balance of the Notes then were approximately $52,000.
"We are pleased to have completed the debt restructuring exercise that was announced back in September 2015," commented Victor Lee, President and CEO of Ascent Solar Technologies, Inc. "All our assets will be officially released by the note holder, which will give the Company more financial flexibility going forward."
EnerPlex Debuts Jumpr Fit & Kickr Mini Product Lines at CES 2016
1/6/16, 5:00 AM
THORNTON, CO -- (Marketwired) -- 01/06/16 -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the company's EnerPlex™ series of consumer products, announced today the Company's EnerPlex Division announced the debut of two new product lines at CES 2016 in Las Vegas: the Qi and FastCharge enabled Jumpr Fit platform and Kickr Mini.
These new products will be on exhibition for the public during CES 2016.
The Kickr Mini is a lightweight 8watt solar charging and battery solution which folds to the size of a smartphone. Equipped with an integrated 5,000mAh battery, the Kickr Mini is the most powerful pocket-sized solar power generation and storage solution available.
The Jumpr Fit platform is the next generation of power-banks from EnerPlex; refined styling and ultra-thin design make the Jumpr Fit family a natural selection for all consumers who need easy-to-carry power. Furnished with dual lightning and micro-USB tethers the Jumpr Fit can charge not only smartphones and other electronics, but wearable electronics as well, such as Fitbit Garmin and others. The Jumpr Fit will come in 3 capacities: 3,000mAh, 6,000mAh and 12,000mAh and will also come with the option for cutting edge Qi and QuickCharge capabilities.
EnerPlex Announces Retail Partnership With eBags
1/4/16, 5:00 AM
THORNTON, CO -- (Marketwired) -- 01/04/16 -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI), a developer and manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into the Company's EnerPlex™ series of consumer products, announced today the Company's EnerPlex brand has launched a retail partnership with eBags, the world's most trusted online destination for bags and all things travel.
EnerPlex products are available at eBags here.
Peter Cobb, EVP and co-founder of eBags said, "At eBags we continually strive to improve the travel experience. Our customers want to stay connected no matter the journey or destination, and our partnership with EnerPlex provides the perfect solution for the traveler who ventures off the grid but needs to remain powered up."
"EnerPlex products in our mobile vertical are designed with the business and leisure traveler in mind; this makes a natural partnership between eBags and EnerPlex who are looking to serve similar markets." said Rafael Gutierrez, SVP and COO of Ascent Solar & EnerPlex.
WHITTIER, CA -- (Marketwired) -- 11/12/15 -- New Generation Consumer Group Inc. (OTC PINK: NGCG) - New Generation Consumer Group Inc. will be hosting an open house to all stakeholders, located at 12411 Slauson, Suite B, Whittier, CA 90606 on Friday, November 20th from 10am - 2pm PT.
Excuse, New Generation Consumer Groups' flavor infused premium Vodka, will be on hand and available for taste testing in all five (5) delectable flavors: Peach, Pineapple-Coconut, Chocolate, Green Apple, and Strawberry. Attendees at the open house who sample Excuse may be asked which flavors they prefer. Top choices will be considered to be first in the upcoming production run.
Excuse is NGCG's premium Vodka line and is scheduled to be rolled out for domestic distribution. This top shelf flavor infused Vodka based liqueur has a world-class taste that will appeal to most discriminating palates.
NGCG will also have the all-new bottled Hemp Refreshers available for taste testing. Hemp Refreshers will be available in the three (3) flavors: Kiwi Strawberry, Pineapple Orange, and the re-formulated flavor Cucumber Lime (previously Cucumber Melon). In addition to the beverages, there will be several other delicious NGCG products available for sampling.
Come join us. Sample our products. Meet many of the NGCG team including celebrity fighter, The World's Most Dangerous Man, UFC Hall of Famer, and four-time world champion, Ken Shamrock. Autographs and pictures welcome. Des W. Woodruff, NGCG's new consultant, will also be at the open house and mingling with shareholders.
I'm with you money-money. Been here since .007. DNRG
News out!
MARLBOROUGH, Mass., Oct. 21, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced that it has selected two compounds for cosmetic product development ("cosmeceuticals") based on its proprietary self-delivering RNAi (sd-rxRNA®) platform.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXI-231, an sd-rxRNA compound developed to target Tyrosinase (TYR), has been selected to advance in to cosmetic product development. TYR is a key enzyme in the synthesis of melanin, the pigment that gives human skin, hair and eyes their color. RXI-231 lead to a visible reduction of pigmentation in melanocytes in a 3-dimensional tissue culture model of human epidermis. Results in this model show that RXI-231 is approximately one hundred times more potent than kojic acid, a well-characterized skin lightening agent.
RXI-185, an sd-rxRNA compound developed to target Collagenase (MMP1), has been selected to advance in to cosmetic product development. Collagenases are enzymes that break the peptide bonds in collagen. Matrix metalloproteinase 1 (MMP1) is a collagenase involved in the breakdown of extracellular matrix that specifically cleaves collagen I, II and III. Results from studies show a pronounced reduction in MMP1 mRNA levels that correspond to a similar reduction in MMP1 enzyme activity in cell culture in vitro. RXI-185 is nominated for development as a product that may improve skin appearance.
These two targets were selected because they have great potential as clinically relevant pharmaceutical gene targets as well as cosmeceutical targets. The Company is actively testing other sd-rxRNAs targeting TYR and MMP1 for possible therapeutic development.
The term 'cosmeceuticals' refers to compounds that affect the appearance of the skin. For example, by targeting tyrosinase, a superficial reduction of melanin could potentially change the appearance of the darkened skin spots known as age spots and freckles or lighten the skin overall. Cosmeceuticals can make no preventative nor therapeutic claims and may be developed more rapidly than therapeutics, therefore the path to market may be much shorter and less expensive.
"The selection of these two cosmetic product candidates opens the door for additional business development opportunities with both small and large companies that are focusing on non-therapeutic skin health," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He further added, "The versatility of MMP1 and TYR, which are relevant for both cosmetic and therapeutic use, are a unique match with our sd-rxRNA platform, allowing us to advance different compounds in both areas of development. This approach further supports our efforts to increase shareholder value."
Dr. Cauwenbergh will present data from the Company's research and clinical programs today at 1:30 p.m. PDT at the Bio Investor Forum in San Francisco, CA. The presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com.
Ok I have some funds. What does L2 look like. Not at my computer
Tapped the .013. Need to sell some funds. To hit some more
Who dat!! Burrhead!! Who dat!!
That's ok. Who dat!! From Delcambre La.
Saints fan here also!!
I agree. I've been here since .007 and still sitting on most of my original shares. This isn't the first time it dips then runs. We need some news and buying volume!
News out!
News out!!!!
Not one oz. of fear in me. This company is strong. Government partnership. 1 bil in investment capital DNRG. Multiple $$$$. Typical Friday!! Up list by end of summer.
Yes I got in at .007 just a few weeks ago. This is crazy!!!
Rajun where are you from. I'm in Delcambre.
I can see this up listing by end of summer. IMO. Hold tight!!!
Still holding my .007's. No stopping this train!!
.007's. Kicking some a$$ now boys
I'll slap 72
Let me slap that 40k
Hello all. I got in this morning at .006. Still have some funds left. I'll use them when the time is right. DNRG!
Lol. Ok!! Ken second round!!
Sorry honey but I'll take a friendly bet on that. Kimbo should have stuck to street fighting. Ken has been in mma since the beginning.
Long here!